Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether endostar (recombinant human
endostatin)with cisplatin and capecitabine (Xeloda) as 1st line treatment in the advanced
gastric cancer is effective and safe.